Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 8/20 | 0.53 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.46 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4949772 | 0.97 | HTR1A (0.50) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4949750 | 0.97 | HTR1A (0.49) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4945206 | 0.95 | ADRA2A (0.52) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4949467 | 0.92 | HTR1A (0.43) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4950079 | 0.89 | HTR1A (0.42) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4950844 | 0.89 | HTR1A (0.42) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4948338 | 0.89 | HTR1A (0.41) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4952024 | 0.86 | HTR1A (0.53) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4950306 | 0.83 | HTR1A (0.50) | HTR1AADRA2AADRA2CADRA1DADRA1A | |
| SCHEMBL4949448 | 0.83 | HTR1A (0.49) | HTR1AADRA2AADRA2CADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | claimed |
| JP-2008526700-A | — | — | 2008-07-24 | — | — | JP | claimed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | claimed |
| EP-1761524-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2007-03-14 | — | — | EP | claimed |
| WO-2006072430-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2006-07-13 | — | — | WO | claimed |
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | SCHWARZ PHARMA AG (DE) | 2008-08-14 | — | — | US | disclosed |
| EP-1761524-B1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SANOL ARZNEI SCHWARZ GMBH (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1761524-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006072430-A1 | PHENYL DIAZEPANE CARBOXAMIDES AND ANNELATED PHENYL PIPERAZINE CARBOXAMIDES CONTAINING OXYGEN AND USED AS DOPAMINE D3 ANTAGONISTS | SCHWARZ PHARMA AG (DE) | 2006-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194539-A1 | Phenyl Diazepane Carboxamides and Annelated Phenyl Piperazine Carboxamides Containing Oxygen and Used as Dopamine D3 Antagonists | DRD3, DRD2, DRD1 | HTR1A 206/4885ADRA2A 95/4885ADRA2C 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.